The aim of treatment in patients at high risk for fractures is to reduce the risk of a first or a subsequent fracture. New data are available on the antifracture effects and side-effects of antiresorptive and osteoanabolic drugs, and new emerging therapies with new modes of action are on the horizon.
INTRODUCTION
During recent years, identification of 50þ patients at risk for fractures and indications for treatment has broadened from the concept of osteoporosis and bone strength toward integrating clinical risk factors for fractures. In addition, general measures are recommended in all drug-treated patients: correction of secondary osteoporosis and other metabolic bone diseases, adequate calcium and vitamin D intake, regular weight-bearing exercises, prevention of falls, stop smoking and limitation of alcohol intake. These concepts have been integrated in recent new or updated guidelines on fracture prevention [1] [2] [3] .
In this manuscript, we will discuss the recent literature on the currently available antiosteoporotic drugs in patients older than 50 years with high fracture risk and review the data on promising new drug developments.
CALCIUM AND VITAMIN D
In the context of adequate calcium homeostasis and fracture prevention, new data are available on the pivotal tandem role of calcium and vitamin D.
An expert panel concluded that, based on available randomized controlled trials (RCTs) only, the combination of calcium and vitamin D versus placebo has been shown to decrease the risk of fractures [4] . In a pooled analysis, it was found that daily 800 IU of vitamin D is associated with a reduction in hip fractures of 30% and in nonvertebral fractures of 14% [5] . Apart from the effect of vitamin D on bone, vitamin D supplementation is also associated with fall reduction in the elderly. Higher dosages of 1500-2000 IU vitamin D per day as suggested by the Endocrine Society Task Force are regarded as premature [4] .
To investigate which dosage of vitamin D is necessary for supplementation, Gallagher et al. [6 & ] performed a RCT with placebo and different dosages of vitamin D: they showed that daily supplements of vitamin D 800 IU/d and higher are able to increase serum 25(OH)D3 levels after 6 months above 50 nmol/l in 97.5% of healthy postmenopausal women, emphasizing that 800 IU is sufficient, at least in the majority of patients. In line with these findings, in a Dutch open study [7] in patients with a recent fracture, around 80% achieved serum levels of greater than 50 nmol/l, at any baseline 25(OH)D level below 50 nmol/l. It was concluded that in daily practice a dose of 800 IU/vitamin D is sufficient in most of these patients, but that follow-up measurements of serum levels can be useful to check adherence [7] .
In spite of the well documented effectiveness of daily vitamin D supplementation, prescription in patients with a hip fracture is far from optimal: only 20% receive vitamin D supplementation at the time of their fracture and after the event [8] .
Total daily calcium intake should be 1000-1200 mg [9] . To achieve these levels, dietary adaptations or calcium supplements should be adapted to baseline calcium intake.
Issues on the research agenda are whether clinically important differences exist between different formulations, for example in patients with achlorhydria and/or patients using proton pump inhibitors, and potential different requirements for premenopausal women, men and nonwhite populations [9] . However, the main topic of discussion is about signals that a higher calcium intake could increase the risk of cardiovascular events, but the data are still conflicting [9, 10] .
BISPHOSPHONATES
Of the antiresorptive drugs, bisphosphonates are the current cornerstones in fracture prevention. For oral alendronate and risedronate, and for (intravenous) zoledronic acid, a reduction in vertebral, nonvertebral and hip fractures was documented [11] . In a study [12] with zoledronic acid in which only hip fracture patients were enrolled, a reduction not only in fractures was observed, but also in mortality [12] . Bisphosphonates are generally well tolerated, but, as with other drugs, there are some side-effects, particularly upper gastrointestinal side-effects are well known.
Both generic alendronate and risedronate are available: their cost price is low, although a large variation was observed, varying from 4 Euro per year to around 300 Euro per year in Europe [13] . Recently, it was suggested that generic alendronate might not have the same tolerability and efficacy as branded alendronate in the first weeks after starting treatment in patients with a recent fracture. In a randomized double-blind study [14 & ] after 4 weeks, the decrease in bone resorption was significantly lower and abdominal pain significantly higher in patients with generic alendronate compared with branded alendronate. After 12 weeks no differences were found between the groups.
Last decade two other side-effects became apparent, osteonecrosis of the jaw (ONJ) and atypical femur fractures (AFFs) [15] . Both are supposed to be related to the low bone turnover state that is induced by long-term bisphosphonate treatment. The high incidence of ONJ is a major side-effect of high doses of zoledronic acid that are used in cancer patients (in 1-10% of patients) [15] . However, in osteoporotic patients treated with bisphosphonates in the much lower doses used for fracture prevention, the relative risk is still doubled or even higher, but the incidence is low (<0.01%) [15] .
The occurrence of AFF is another side-effect of bisphosphonates, which has been re-reviewed in great detail by an American Society of Bone and Mineral Research (ASBMR) task force [16] .
The exact cause is still not fully elucidated. It is important to realize that these AFFs may also occur KEY POINTS (Only) for alendronate, risedronate, zoledronic acid and denosumab, a reduction in vertebral and nonvertebral (including hip) fractures has been shown.
Fracture reduction of the above-mentioned antiresorptive agents exceed the risk of the rare sideeffects such as AFF and ONJ.
Long-term data (up to 8 years) of denosumab show a sustained increase in BMD and a stable low incidence of vertebral and nonvertebral fractures.
New antiosteoporotic drugs are under development: monoclonal antibodies against sclerostin seem to have a very strong bone formation stimulating effect.
in frail elderly without (ever) bisphosphonate use. Although the relative risk of patients with AFFs taking bisphosphonates versus nonusers is increased, the absolute risk of AFFs in patients on bisphosphonates is low, ranging from 3.2 to 50 cases per 100 000 person-years. However, long-term use may be associated with higher risk ($100 per 100 000 personyears). When bisphosphonates are stopped, the risk of an AFF may decline. AFF often have prodromal signs: chronic pain in the upper leg around the hips is suspect in a patient with long-term use of bisphosphonates. In a recent review of the data of the FDA, it was stated that an increased risk of AFF has been found with all bisphosphonates [17] .
Several case reports indicate a positive effect of teriparatide on healing of ONJ. The results of a study [18] in 14 patients show some, but inconsistent evidence of accelerated healing of AFFs during treatment with teriparatide.
DENOSUMAB
Denosumab is a new approach to the prevention of osteoporotic fractures. It is a fully human monoclonal antibody with high specificity for the human receptor activator of the nuclear factor kB ligand (RANKL), thereby reducing osteoclast formation, activity and survival, leading to decreased bone resorption [19] (Fig. 1) [20] . In postmenopausal women with osteoporosis, denosumab has been shown to decrease bone turnover markers, increase BMD of the spine and hips and to have a broad spectrum of prevention of vertebral, nonvertebral and hip fractures [21] .
In the extension of the above-mentioned phase III trial , denosumab treatment for 6 years remained well tolerated, maintained reduced bone turnover, continued to increase BMD and fracture incidence remained low [22] . Incidence rates of adverse events did not increase over time. Six participants had ONJ and one had an AFF, both confirmed by adjudication.
Very recently, the 8 years of data of denosumab were presented at the ASBMR meeting, which confirm the 6 years data: a sustained increase in BMD, up to 18.5% in the spine and 8.2% at the hips, a stable low incidence of both vertebral and nonvertebral fractures over time [23] . Odanacatib is a selective cathepsin K inhibitor: it reduces the degradation of collagen type 1 in bone. Monoclonal antibodies against sclerostin antagonizes the WnT pathway, which leads to reduced bone formation (adapted from [20] ).
In order to get better insight into the mechanism by which denosumab treatment leads to large increases in BMD and stabilization of fracture risk over time, several individuals of the FREEDOM study participated in additional imaging studies, particularly focusing on cortical bone. Denosumab significantly improved both vBMD and BMC from baseline and placebo, assessed by Quantitative CT, in the integral, trabecular, subcortical, and cortical hip compartments, all of which are relevant to bone strength [24] .
In a study [25 & ] with a direct comparison with an active drug (alendronate), denosumab resulted in a greater reduction in cortical porosity which might be due to greater inhibition of intracortical remodeling.
Very recently, it was suggested that continuous modeling-based bone formation could explain the sustained increase in hip BMD with denosumab treatment, based on histomorphometic data in an animal model [26] .
All the three above-described studies suggest a favorable effect of denosumab on cortical bone, which could be clinically relevant, since the majority of fractures are nonvertebral. Nevertheless, whether denosumab indeed has such a strong positive effect on cortical bone strength that nonvertebral fracture risk decreases substantially more than for the other antiosteoporotic drugs has to be investigated further on.
In contrast to bisphosphonates, cessation of denosumab treatment results in an immediate increase in bone resorption and formation, and, subsequently, bone loss. However, in patients of the FREEDOM study [27] who stopped treatment with denosumab after 3 years' treatment, there did not appear to be an excess in fracture risk after treatment cessation with denosumab compared with placebo during the off-treatment period for up to 24 months.
In a crossover study, the majority preferred denosumab to weekly alendronate, regardless of the treatment sequence, and had more positive perceptions of denosumab than alendronate. This higher preference was associated with better adherence [28] (Fig. 1 ).
STRONTIUM RANELATE
Strontium ranelate has long been regarded as an effective antiosteoporotic drug with unique working mechanisms, since it decreases bone resorption, but also increases bone formation, a favorable combination [29] . However, in a recent study [30] using 90 baseline and 1-year paired transiliac bone biopsies, analyzed by 2-dimensional histology, static bone formation parameters remained stable, whereas dynamic bone formation parameters decreased significantly.
A serious issue is the elevated cardiovascular risk in patients using strontium ranelate: recently, the European Medicines Agency decided, based on a pooled analysis of the seven studies in postmenopausal women (3.803 patients on strontium ranelate, but mainly driven by the Treatment of Peripheral Osteoporosis study [29] ), that strontium ranelate should not be used in patients with current or past history of ischaemic heart disease (such as angina or a heart attack), peripheral arterial disease (obstruction of large blood vessels, often in the legs) or cerebrovascular disease (diseases affecting the blood vessels supplying the brain, such as stroke) and strontium ranelate should not be used in patients with hypertension (high blood pressure) that is not adequately controlled by treatment [31] . In contrast, in the clinical practice research datalink database, no increased cardiovascular risk was found in patients with strontium ranelate [32] .
PARATHYROID HORMONE AND ITS ANALOGUES
In contrast to antirestorptives, parathyroid hormone (PTH) and teriparatide, a recombinant human PTH 1-34 fragment (rhPTH 1-34), are the only currently available true osteoanabolic drugs as they have been shown to increase bone formation, as measured by bone markers and by histology [33, 34] . Daily application of PTH analogues increases the production of RANKL and interferes with the WnT signaling pathway, by blocking sclerostin, leading to stimulated bone formation [34, 35] .
Compared with antiresorptives, teriparatide had the highest risk reduction of fractures and the highest probability of being ranked first for efficacy. However, differences to denosumab, zoledronate, risedronate, ibandronate, and alendronate were not statistically significant [11] .
Teriparatide combined with denosumab increased BMD more than either agent alone and more than has been reported with other approved therapies [36] .
In a large observational study [37] , in patients with severe osteoporosis and with co-morbidities and co-medication, all treated with teriparatide for 18 months, a 47% decrease in fracture rate in the last 6-month period compared with the first 6-month period was observed. Moreover, a substantial decrease in back pain was found and an increase in quality of life, which was sustained during subsequent treatment with other medications [38] .
Glucocorticoids induce apoptosis of osteoblasts and osteocytes, with a subsequent inhibiting effect on bone formation. Thus, an osteoanabolic drug would be preferred to a bisphosphonate for the treatment of glucocorticoid-induced osteoporosis (GIOP) [39] . In a study [40] in GIOP, in which teriparatide was more effective than alendronate on BMD and vertebral fracture prevention, positive correlations were found between changes in a biochemical marker of bone formation and improvement of biomechanical properties, which supports the use of PINP as a surrogate marker of bone strength in teriparatide-treated GIOP patients [41] .
In an 18-month trial in men with GIOP, teriparatide showed larger improvements in spinal BMD, microstructure and finite element-derived strength than risedronate [42] .
CATHEPSIN K INHIBITORS
Cathepsin K is a protease with intense collagenase activity that is predominantly expressed in osteoclasts and is able to degrade collagens I and II [43] ( Fig. 1) . For odanacatib, a selective cathepsin Kinhibitor, reliable data are available from phase II studies, and the phase III study is ongoing. In an RCT in 339 patients, odanacatib 50 mg once weekly was compared with placebo: a greater increase in the BMD of both the lumbar spine and the total hip was observed: 5.5 versus À0.2% and 3.2 versus À0.9%, respectively [44] . Although this increase is significant, and possibly larger than with oral bisphosphonates, the effect on fracture reduction is yet unknown. Interestingly, and in contrast to antiresorptives by which bone resorption and formation are coupled, during treatment with odanacatib, there seems to be some uncoupling between bone resorption and formation. Although serum CTX I decreased during treatment with odanacatib, similarly to antiresorptive drugs, markers of bone formation decreased only initially, and then gradually returned back to baseline levels. This suggests that odanacatib is able to uncouple bone resorption from bone formation. Recently, it was suggested that deletion of cathepsin K enhances bone formation in vivo by increasing the generation of osteoclast-derived sphingosine kinase, which can stimulate bone formation [45 && ]. In postmenopausal women with low BMD, odanacatib over 2 years decreased bone resorption, maintained bone formation, increased areal and volumetric BMD, and increased estimated bone strength at both the hip and the spine [46] . Discontinuation of odanacatib resulted in reversal of treatment effects within 1 year [47] . At this time, we can only speculate whether the uncoupling is not only scientifically and theoretically, but also clinically relevant. A phase 3 trial with odanacatib with hip fracture prevention as primary endpoint is ongoing. Also other cathepsin K inhibitors are in study.
Monoclonal antibodies against sclerostin
Thanks to the study [48] of rare human bone sclerosing diseases affecting bone, a decade ago mutations were discovered in the components of the canonical Wnt signaling machinery. Sclerosteosis and van Buchem disease are two closely related rare bone disorders resulting in endosteal hyperostosis, which are characterized by progressive generalized osteosclerosis, particularly in the mandible and skull, sometimes complicated by entrapment of cranial nerves [49] . Sclerosteosis is caused by a genetic defect on chromosome 17q12-21, encoding for the protein sclerostin; in van Buchem disease a modification downstream of the same gene was found. In healthy adults, sclerostin is expressed by osteocytes, but not in patients with sclerosteosis and van Buchem disease. Sclerostin inhibits bone formation by antagonizing the Wnt signaling pathway, which plays an important role in the bone formation [48, 20] (Fig. 1) .
As a result, monoclonal antibodies against sclerostin have been developed. In a recently published dose-escalating single-dose phase 1 trial, it was demonstrated that one single (subcutaneous) injection of a monoclonal antibody against sclerostin markedly increased bone formation markers and BMD: an increase in BMD of 5.3% at the lumbar spine and 2.8% at the total hip was found 85 days after one single injection of 10 mg/kg [50] . Recently, it was shown that treatment during 1 year with rosozumab, a monoclonal antibody against sclerostin, induces a larger increase in trabecular and cortical BMD than placebo, but also compared with teriparatide ( [51] : new, updated reference since last week). A phase III trial is currently underway. Blosozumab, another monoclonal antibody against sclerostin, was superior to placebo at all dosages [52] .
These data are promising, and the very strong bone formation stimulating effect may make it indicated in patients with severe osteoporosis, but the optimal scheme and dosage should be further investigated.
CONCLUSION
Drugs that inhibit bone remodeling are currently the mainstream for fracture prevention in patients at high risk for osteoporotic fractures. Oral bisphosphonates can be associated with upper gastrointestinal side-effects, and all bisphosphonates and denusomab with the rarely occurring AFFs and bone necrosis of the jaw. Teriparatide on the contrary, is an osteoanabolic drug that increases bone formation more than resorption, and is indicated after treatment failure or intolerance of antiresorptives.
Calcium and vitamin D intake should be sufficient. New potential developments in antiresorptive drugs include odanacatib, a selective inhibitor of cathepsin K, and, in anabolic drugs, monoclonal antibodies against sclerostin. These are promising new drugs with new mechanisms of action, as they are able to disconnect the normal coupling between bone resorption and bone formation.
